New hope for kids with rare sanfilippo syndrome? early trial launches
NCT ID NCT06488924
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase study tests a new drug called JR-446 in 10 children with mucopolysaccharidosis type IIIB (Sanfilippo syndrome type B), a rare genetic disease that affects the brain and body. The drug is given through an IV and aims to be safe and possibly help manage the condition. The main goals are to check safety and how the drug works in the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- JR-446 (a drug given by IV infusion)
- What this could lead to
- If it works, this could point toward a treatment that slows or manages MPS IIIB symptoms in children.
- What could go wrong
- This is a very early, small trial (only 10 children) focused on safety. It may not show clear benefit, and side effects are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MUCOPOLYSACCHARIDOSIS III-B are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hiroshima University Hospital
RECRUITINGHiroshima, Japan
Contact Phone: •••-•••-••••
-
National Center for Child Health and Development
RECRUITINGTokyo, Japan
Contact Phone: •••-•••-••••
-
University of the Ryukyus Hospital
RECRUITINGOkinawa, Japan
Contact Phone: •••-•••-••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.